Abstract
Arginine vasopressin (AVP) V2 receptor antagonism is a new approach to the management of hyponatraemia in congestive heart failure (CHF). The aim of this study was to investigate the efficacy and safety of satavaptan, an oral AVP V2-receptor antagonist, in patients with dilutional hyponatraemia.
Original language | English |
---|---|
Pages (from-to) | 327 - 336 |
Number of pages | 10 |
Journal | European Journal of Heart Failure |
Volume | 13 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2011 |